[
  {
    "ts": null,
    "headline": "Can Biogen’s (BIIB) Immunology Pipeline Moves Reshape Its Competitive Edge in Autoimmune Disease?",
    "summary": "Biogen and partner UCB recently announced upcoming presentations at the American College of Rheumatology 2025 conference highlighting positive Phase 3 data for dapirolizumab pegol in treating systemic lupus erythematosus (SLE), supported by efficacy across multiple endpoints and promising safety data, especially in women of childbearing age. This follows a series of pipeline enhancements for Biogen in immunology and rare diseases, including a new licensing agreement with Vanqua Bio for a...",
    "url": "https://finnhub.io/api/news?id=61c6334ca2f7fb90a8a09cbefa2d6bfc4ee3da7f99f341fe237b4595b641943a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761318530,
      "headline": "Can Biogen’s (BIIB) Immunology Pipeline Moves Reshape Its Competitive Edge in Autoimmune Disease?",
      "id": 137218241,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen and partner UCB recently announced upcoming presentations at the American College of Rheumatology 2025 conference highlighting positive Phase 3 data for dapirolizumab pegol in treating systemic lupus erythematosus (SLE), supported by efficacy across multiple endpoints and promising safety data, especially in women of childbearing age. This follows a series of pipeline enhancements for Biogen in immunology and rare diseases, including a new licensing agreement with Vanqua Bio for a...",
      "url": "https://finnhub.io/api/news?id=61c6334ca2f7fb90a8a09cbefa2d6bfc4ee3da7f99f341fe237b4595b641943a"
    }
  },
  {
    "ts": null,
    "headline": "Biogen licenses a possible immune drug from OrbiMed-backed biotech",
    "summary": "The preclinical drug from Vanqua Bio is designed to inhibit “C5aR1,” a part of the immune system that regulates inflammation.",
    "url": "https://finnhub.io/api/news?id=430f54db24c01f564e20d5cc23e90efc086cbc6e5b37068df150cdb2c6fe104d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761317880,
      "headline": "Biogen licenses a possible immune drug from OrbiMed-backed biotech",
      "id": 137218242,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "The preclinical drug from Vanqua Bio is designed to inhibit “C5aR1,” a part of the immune system that regulates inflammation.",
      "url": "https://finnhub.io/api/news?id=430f54db24c01f564e20d5cc23e90efc086cbc6e5b37068df150cdb2c6fe104d"
    }
  },
  {
    "ts": null,
    "headline": "Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key",
    "summary": "Biogen is expected to top earnings forecasts again as new products offset declining multiple sclerosis drug sales.",
    "url": "https://finnhub.io/api/news?id=2f135c991b8bd81bed242e0de237a74c1fb28c059ff6a9fc7f7e10086ff0493a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761316380,
      "headline": "Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key",
      "id": 137218243,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen is expected to top earnings forecasts again as new products offset declining multiple sclerosis drug sales.",
      "url": "https://finnhub.io/api/news?id=2f135c991b8bd81bed242e0de237a74c1fb28c059ff6a9fc7f7e10086ff0493a"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio",
    "summary": "The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many inflammatory diseases CAMBRIDGE, Mass. and CHICAGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s preclinical, oral C5aR1 antagonist. This agreement strengthens Biogen’s immunology strategy by advancing a proven immune mechanism with the potential to address a",
    "url": "https://finnhub.io/api/news?id=def4462feb7870282bd358c66c226dd2dc0f782567e5b1939573310a1214ddf1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761305400,
      "headline": "Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio",
      "id": 137218244,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many inflammatory diseases CAMBRIDGE, Mass. and CHICAGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s preclinical, oral C5aR1 antagonist. This agreement strengthens Biogen’s immunology strategy by advancing a proven immune mechanism with the potential to address a",
      "url": "https://finnhub.io/api/news?id=def4462feb7870282bd358c66c226dd2dc0f782567e5b1939573310a1214ddf1"
    }
  },
  {
    "ts": null,
    "headline": "3 Profitable Stocks We Steer Clear Of",
    "summary": "While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, \"Your margin is my opportunity\".",
    "url": "https://finnhub.io/api/news?id=d044573eddb4d944629ed0480985ac66e3fce8c31d96be12dd156189d53ec234",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761281109,
      "headline": "3 Profitable Stocks We Steer Clear Of",
      "id": 137218245,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, \"Your margin is my opportunity\".",
      "url": "https://finnhub.io/api/news?id=d044573eddb4d944629ed0480985ac66e3fce8c31d96be12dd156189d53ec234"
    }
  }
]